{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T15:34:19Z","timestamp":1787844859875,"version":"build-2784847793"},"reference-count":139,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,6,27]],"date-time":"2023-06-27T00:00:00Z","timestamp":1687824000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Psychiatry"],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Our objective was to conduct a systematic review and meta-analysis of adverse effects on sleep in patients with schizophrenia receiving antipsychotic treatment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A systematic search was performed in PubMed, Cochrane Central, Embase, Toxline, Ebsco, Virtual Health Library, Web of Science, SpringerLink, and in Database of abstracts of Reviews of Effects of Randomized Clinical Trials to identify eligible studies published from January 1990 to October 2021. The methodological quality of the studies was evaluated using the CONSORT list, and the Cochrane bias tool. Network meta-analysis was performed using the Bayesian random-effects model, with multivariate meta-regression to assess the association of interest.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>87 randomized clinical trials were identified that met the inclusion criteria, and 70 articles were included in the network meta-analysis. Regarding the methodological quality of the studies, 47 had a low or moderate bias risk. The most common adverse effects on sleep reported in the studies were insomnia, somnolence, and sedation. The results of the network meta-analysis showed that ziprasidone was associated with an increased risk of insomnia (OR, 1.56; 95% credible interval CrI, 1.18\u20132.06). Several of the included antipsychotics were associated with a significantly increased risk of somnolence; haloperidol (OR, 1.90; 95% CrI, 1.12\u20133.22), lurasidone (OR, 2.25; 95% CrI, 1.28\u20133.97) and ziprasidone (OR, 1.79; 95% CrI, 1.06\u20133.02) had the narrowest confidence intervals. In addition, perphenazine (OR, 5.33; 95% CrI, 1.92\u201314.83), haloperidol (OR, 2.61; 95% CrI, 1.14\u20135.99), and risperidone (OR, 2.41; 95% CrI, 1.21\u20134.80) were associated with an increased risk of sedation compared with placebo, and other antipsychotics did not differ. According to the SUCRAs for insomnia, chlorpromazine was ranked as the lowest risk of insomnia (57%), followed by clozapine (20%), while flupentixol (26 %) and perospirone (22.5%) were associated with a lower risk of somnolence. On the other hand, amisulpride (89.9%) was the safest option to reduce the risk of sedation.<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion<\/jats:title><jats:p>Insomnia, sedation, and somnolence were the most frequent adverse effects on sleep among the different antipsychotics administered. The evidence shows that chlorpromazine, clozapine, flupentixol, perospirone, and amisulpride had favorable safety profiles. In contrast, ziprasidone, perphenazine, haloperidol, and risperidone were the least safe for sleep.<\/jats:p><\/jats:sec><jats:sec><jats:title>Systematic review registration<\/jats:title><jats:p><jats:ext-link>https:\/\/www.crd.york.ac.uk\/prospero\/display_record.php?ID=CRD42017078052<\/jats:ext-link>, identifier: PROSPERO 2017 CRD42017078052.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fpsyt.2023.1189768","type":"journal-article","created":{"date-parts":[[2023,6,27]],"date-time":"2023-06-27T11:53:10Z","timestamp":1687866790000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":24,"title":["Adverse effects of antipsychotics on sleep in patients with schizophrenia. Systematic review and meta-analysis"],"prefix":"10.3389","volume":"14","author":[{"given":"Yarmila Elena","family":"Valencia Carlo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo Arturo","family":"Saracco-Alvarez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ver\u00f3nica Angela","family":"Valencia Carlo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"V\u00e1zquez Vega","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillermina","family":"Natera Rey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raul Ivan","family":"Escamilla Orozco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,6,27]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1056\/NEJMra1808803","article-title":"Schizophrenia","volume":"381","author":"Marder","year":"2019","journal-title":"N Engl J Med."},{"key":"B2","doi-asserted-by":"publisher","first-page":"939","DOI":"10.2165\/00023210-200822110-00004","article-title":"Sleep disturbances in patients with schizophrenia: Impact and effect of antipsychotics","volume":"22","author":"Cohrs","year":"2008","journal-title":"CNS Drugs."},{"key":"B3","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1080\/09540260500104516","article-title":"Sleep disturbance in schizophrenia","volume":"17","author":"Monti","year":"2005","journal-title":"Int Rev Psychiatry."},{"key":"B4","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1007\/978-3-7643-8561-3_24","article-title":"The effect of typical and atypical antipsychotic drugs on sleep of schizophrenic patients","author":"Winokur","year":"2008","journal-title":"En: Serotonin and Sleep: Molecular, Functional and Clinical Aspects"},{"key":"B5","doi-asserted-by":"publisher","first-page":"100070","DOI":"10.1016\/j.bbih.2020.100070","article-title":"Nutritional psychiatry in the treatment of psychotic disorders: current hypotheses and research challenges","volume":"5","author":"Teasdale","year":"2020","journal-title":"Brain Behav Immun Health."},{"key":"B6","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1017\/S204579601500044X","article-title":"Childhood adversity and psychosis: generalised or specific effects?","volume":"25","author":"Longden","year":"2016","journal-title":"Epidemiol Psychiatr Sci."},{"key":"B7","doi-asserted-by":"publisher","first-page":"43","DOI":"10.2147\/PROM.S42735","article-title":"Nonadherence with antipsychotic medication in schizophrenia: challenges and management strategies","volume":"5","author":"Haddad","year":"2014","journal-title":"Patient Relat Outcome Meas"},{"key":"B8","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.eurpsy.2004.06.031","article-title":"Impact of present and past antipsychotic side effects on attitude toward typical antipsychotic treatment and adherence","volume":"19","author":"Lambert","year":"2004","journal-title":"Eur Psychiatry."},{"key":"B9","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.jbi.2014.03.014","article-title":"Exploring the associations between drug side-effects and therapeutic indications","volume":"51","author":"Wang","year":"2014","journal-title":"J Biomed Inform."},{"key":"B10","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/S2215-0366(19)30416-X","article-title":"Comparative effects of 18 antipsychotics on metabolic function in patients with Schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysis","volume":"7","author":"Pillinger","year":"2020","journal-title":"Lancet Psychiatry."},{"key":"B11","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1097\/JCP.0000000000000665","article-title":"Activating and sedating adverse effects of second-generation antipsychotics in the treatment of schizophrenia and major depressive disorder: absolute risk increase and number needed to harm","volume":"37","author":"Citrome","year":"2017","journal-title":"J Clin Psychopharmacol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/S0140-6736(19)31135-3","article-title":"Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis","volume":"394","author":"Huhn","year":"2019","journal-title":"Lancet."},{"key":"B13","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/j.jsmc.2016.08.001","article-title":"Adverse effects of psychotropic medications on sleep","volume":"11","author":"Doghramji","year":"2016","journal-title":"Sleep Med Clin."},{"key":"B14","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1097\/YIC.0b013e3282f39703","article-title":"Effects of antipsychotic medications on sleep in schizophrenia","volume":"23","author":"Krystal","year":"2008","journal-title":"Int Clin Psychopharmacol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.smrv.2005.05.004","article-title":"Distinguishing sleepiness and fatigue: Focus on definition and measurement","volume":"10","author":"Shen","year":"2006","journal-title":"Sleep Med Rev"},{"key":"B16","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1016\/S0140-6736(13)60733-3","article-title":"Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments metaanalysis","volume":"382","author":"Leucht","year":"2013","journal-title":"Lancet."},{"key":"B17","doi-asserted-by":"publisher","first-page":"e6152","DOI":"10.7759\/cureus.6152","article-title":"Treatment options for acute agitation in psychiatric patients: Theoretical and empirical evidence","volume":"11","author":"Zareifopoulos","year":"2019","journal-title":"Cureus."},{"key":"B18","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1176\/ps.49.2.196","article-title":"Compliance with medication regimens for mental and physical disorders","volume":"49","author":"Cramer","year":"1998","journal-title":"Psychiatr Serv."},{"key":"B19","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.jpsychires.2014.09.013","article-title":"Antipsychotic augmentation with modafinil or armodafinil for negative symptoms of schizophrenia: systematic review and meta-analysis of randomized controlled trials","volume":"60","author":"Andrade","year":"2015","journal-title":"J Psychiatr Res."},{"key":"B20","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1007\/s11910-008-0026-x","article-title":"Pathophysiology of restless legs syndrome: evidence for iron involvement","volume":"8","author":"Connor","year":"2008","journal-title":"Curr Neurol Neurosci Rep."},{"key":"B21","first-page":"380","article-title":"Sleep medicine: restless legs syndrome","volume":"115","author":"Bollu","year":"2018","journal-title":"Mol Med."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.phrs.2013.10.005","article-title":"Controversies in the use of second-generation antipsychotics as sleep agent","volume":"79","author":"Shah","year":"2014","journal-title":"Pharmacol Res"},{"key":"B23","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1002\/wps.20567","article-title":"Management of common adverse effects of antipsychotic medications","volume":"17","author":"Stroup","year":"2018","journal-title":"World Psychiatry."},{"key":"B24","doi-asserted-by":"publisher","first-page":"107704","DOI":"10.1016\/j.neuropharm.2019.107704","article-title":"Antipsychotics: Mechanisms underlying clinical response and side-effects and novel treatment approaches based on pathophysiology","volume":"172","author":"Kaar","year":"2020","journal-title":"Neuropharmacology."},{"key":"B25","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.smrv.2016.05.002","article-title":"The effects of second-generation antipsychotic drugs on sleep variables in healthy subjects and patients with schizophrenia","volume":"33","author":"Monti","year":"2017","journal-title":"Sleep Med Rev."},{"key":"B26","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.euroneuro.2022.11.008","article-title":"Effects of quetiapine on sleep: a systematic review and meta-analysis of clinical trials","volume":"67","author":"Lin","year":"2023","journal-title":"Eur Neuropsychopharmacol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"88","DOI":"10.3390\/medicines5030088","article-title":"Pharmacologic treatment options for insomnia in patients with schizophrenia","volume":"5","author":"Stummer","year":"2018","journal-title":"Medicines."},{"key":"B28","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1111\/jep.12200","article-title":"Does the CONSORT checklist for abstracts improve the quality of reports of randomized controlled trials on clinical pathways? Quality of RCTs on clinical pathway","volume":"20","author":"Cui","year":"2014","journal-title":"J Eval Clin Pract."},{"key":"B29","doi-asserted-by":"publisher","first-page":"c869","DOI":"10.1136\/bmj.c869","article-title":"CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials","volume":"340","author":"Moher","year":"2010","journal-title":"BMJ"},{"key":"B30","unstructured":"2011"},{"key":"B31","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1016\/S0140-6736(15)61478-7","article-title":"Network meta-analysis: a norm for comparative effectiveness?","volume":"386","author":"Higgins","year":"2015","journal-title":"Lancet."},{"key":"B32","doi-asserted-by":"publisher","first-page":"49","DOI":"10.4103\/2229-3485.106383","article-title":"Placebo in clinical trials","volume":"4","author":"Gupta","year":"2013","journal-title":"Perspect Clin Res."},{"key":"B33","unstructured":"EuropeanMedicines Agency (EMA),. Scientific Guidelines for Human Medicinal Products-Clinical Efficacy Safety Guidelines.\n          2020"},{"key":"B34","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/s11739-016-1583-7","article-title":"Network meta-analysis: an introduction for clinicians","volume":"12","author":"Rouse","year":"2017","journal-title":"Intern Emerg Med."},{"key":"B35","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/1741-7015-12-15","volume":"12","author":"Catal\u00e1","year":"2014","journal-title":"BMC Med"},{"key":"B36","doi-asserted-by":"publisher","first-page":"e76654","DOI":"10.1371\/journal.pone.0076654","article-title":"Graphical tools for network meta-analysis in STATA","volume":"8","author":"Chaimani","year":"2013","journal-title":"PLoS ONE."},{"key":"B37","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.jclinepi.2018.02.009","article-title":"Is providing uncertainty intervals in treatment ranking helpful in a network meta-analysis?","volume":"100","author":"Veroniki","year":"2018","journal-title":"J Clin Epidemiol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.jclinepi.2010.03.016","article-title":"Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial","volume":"64","author":"Salanti","year":"2011","journal-title":"J Clin Epidemiol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2019\/2546161","article-title":"Short-term efficacy and safety of IL-17, IL-12\/23, and IL-23 inhibitors brodalumab, secukinumab, ixekizumab, ustekinumab, guselkumab, tildrakizumab, and risankizumab for the treatment of moderate to severe plaque psoriasis: a systematic review and network meta-analysis of randomized controlled trials","volume":"2019","author":"Bai","year":"2019","journal-title":"J Immunol Res."},{"key":"B40","first-page":"14","article-title":"Haloperidol versus risperidone: a comparison of beneficial effect on cognitive function of patients with chronic schizophrenia","volume":"2","author":"Abdolahian","year":"2008","journal-title":"Iran J Psychiatry Behav Sci."},{"key":"B41","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1097\/01.jcp.0000222513.63767.de","article-title":"A randomized, 1-year follow-up study of olanzapine and risperidone in the treatment of negative symptoms in outpatients with schizophrenia","volume":"26","author":"\u00c1lvarez","year":"2006","journal-title":"J Clin Psychopharmacol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1097\/00004850-200209000-00001","article-title":"A 1-year, double-blind, placebo-controlled trial of ziprasidone 40, 80 and 160 mg\/day in chronic schizophrenia: the Ziprasidone Extended Use in Schizophrenia (ZEUS) study","volume":"17","author":"Arato","year":"2002","journal-title":"Int Clin Psychopharmacol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1097\/01.yic.0000177020.26311.a7","article-title":"A double-blind, controlled study of sertindole versus risperidone in the treatment of moderate-to-severe schizophrenia","volume":"21","author":"Azorin","year":"2006","journal-title":"Int Clin Psychopharmacol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/0893-133X(95)00069-P","article-title":"Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial","volume":"14","author":"Beasley CM","year":"1996","journal-title":"Neuropsychopharmacology."},{"key":"B45","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1001\/jamapsychiatry.2015.0241","article-title":"Efficacy and safety of the 3-month formulation of paliperidone palmitate vs placebo for relapse prevention of schizophrenia: a randomized clinical trial","volume":"72","author":"Berwaerts","year":"2015","journal-title":"JAMA psychiatry."},{"key":"B46","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.pnpbp.2003.09.033","article-title":"Olanzapine versus clozapine in treatment-resistant or treatment-intolerant schizophrenia","volume":"28","author":"Bitter","year":"2004","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry."},{"key":"B47","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.1176\/appi.ajp.162.10.1879","article-title":"Olanzapine versus ziprasidone: results of a 28-week double-blind study in patients with schizophrenia","volume":"162","author":"Breier","year":"2005","journal-title":"Am J Psychiatry."},{"key":"B48","doi-asserted-by":"publisher","first-page":"237","DOI":"10.3109\/00048670903487134","article-title":"Amisulpride versus olanzapine in the treatment of schizophrenia in Indian patients: randomized controlled trial","volume":"44","author":"Bhowmick","year":"2010","journal-title":"Aust New Zeal J Psychiatry."},{"key":"B49","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.euroneuro.2004.07.003","article-title":"Comparative efficacy and safety of long-acting risperidone and risperidone oral tablets","volume":"15","author":"Chue","year":"2005","journal-title":"Eur Neuropsychopharmacol."},{"key":"B50","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1097\/00004850-200015010-00002","article-title":"Long-term safety and efficacy of amisulpride in subchronic or chronic schizophrenia. Amisulpride Study Group","volume":"15","author":"Colonna","year":"2000","journal-title":"Int Clin Psychopharmacol."},{"key":"B51","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1007\/s002130000452","article-title":"Zotepine in the prevention of recurrence: a randomised, double-blind, placebo-controlled study for chronic schizophrenia","volume":"150","author":"Cooper","year":"2000","journal-title":"Psychopharmacology."},{"key":"B52","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1176\/ajp.155.7.914","article-title":"Olanzapine compared with chlorpromazine in treatment-resistant schizophrenia","volume":"155","author":"Conley","year":"1998","journal-title":"Am J Psychiatry."},{"key":"B53","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1176\/appi.ajp.2015.14101275","article-title":"Efficacy and safety of brexpiprazole for the treatment of acute schizophrenia: a 6-week randomized, double-blind, placebo-controlled trial","volume":"172","author":"Correll","year":"2015","journal-title":"Am J Psychiatry."},{"key":"B54","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1017\/S1092852900014784","article-title":"The efficacy and safety of lower doses of aripiprazole for the treatment of patients with acute exacerbation of schizophrenia","volume":"11","author":"Cutler","year":"2006","journal-title":"CNS Spectr."},{"key":"B55","doi-asserted-by":"publisher","first-page":"S20","DOI":"10.1097\/JCP.0b013e318169d4ce","article-title":"Four-week, double-blind, placebo-and ziprasidone-controlled trial of iloperidone in patients with acute exacerbations of schizophrenia","volume":"28","author":"Cutler","year":"2008","journal-title":"J Clin Psychopharmacol."},{"key":"B56","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.schres.2007.03.003","article-title":"Efficacy, safety and early response of paliperidone extended-release tablets (paliperidone ER): results of a 6-week, randomized, placebo-controlled study","volume":"93","author":"Davidson","year":"2007","journal-title":"Schizophr Res."},{"key":"B57","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1097\/JCP.0000000000000140","article-title":"Comparison of olanzapine long-acting injection and oral olanzapine: a 2-year, randomized, open-label study in outpatients with schizophrenia","volume":"34","author":"Detke","year":"2014","journal-title":"J Clin Psychopharmacol."},{"key":"B58","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.pnpbp.2003.10.010","article-title":"Double-blind, randomized comparison of olanzapine versus fluphenazine in the long-term treatment of schizophrenia","volume":"28","author":"Dossenbach","year":"2004","journal-title":"Progr Neuropsychopharmacol Biol Psychiatry."},{"key":"B59","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12888-014-0351-3","article-title":"A double-blind, placebo-controlled comparator study of LY2140023 monohydrate in patients with schizophrenia","volume":"14","author":"Downing","year":"2014","journal-title":"BMC Psychiatry."},{"key":"B60","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/j.schres.2013.11.041","article-title":"An evaluation of the safety and efficacy of cariprazine in patients with acute exacerbation of schizophrenia: a phase II, randomized clinical trial","volume":"152","author":"Durgam","year":"2014","journal-title":"Schizophr Res."},{"key":"B61","doi-asserted-by":"publisher","first-page":"e1574","DOI":"10.4088\/JCP.15m09997","article-title":"Cariprazine in acute exacerbation of schizophrenia: a fixed-dose, phase 3, randomized, double-blind, placebo- and active-controlled trial","volume":"76","author":"Durgam","year":"2015","journal-title":"J Clin Psychiatry."},{"key":"B62","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1097\/YIC.0000000000000110","article-title":"Cariprazine in the treatment of schizophrenia: a proof-of-concept trial","volume":"31","author":"Durgam","year":"2016","journal-title":"Int Clin Psychopharmacol."},{"key":"B63","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/j.schres.2016.06.030","article-title":"Long-term cariprazine treatment for the prevention of relapse in patients with schizophrenia: a randomized, double-blind, placebo-controlled trial","volume":"176","author":"Durgam","year":"2016","journal-title":"Schizophr Res."},{"key":"B64","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1097\/00004850-200015030-00001","article-title":"A comparison of the effects of quetiapine (\u2018seroquel') and haloperidol in schizophrenic patients with a history of and a demonstrated, partial response to conventional antipsychotic treatment. PRIZE Study Group","volume":"15","author":"Emsley","year":"2000","journal-title":"Int Clin Psychopharmacol."},{"key":"B65","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1017\/S1461145711001076","article-title":"A randomized trial of paliperidone palmitate and risperidone long-acting injectable in schizophrenia","volume":"15","author":"Fleischhacker","year":"2012","journal-title":"Int J Neuropsychopharmacol."},{"key":"B66","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1192\/bjp.bp.113.134213","article-title":"Aripiprazole once-monthly for treatment of schizophrenia: double-blind, randomised, non-inferiority study","volume":"205","author":"Fleischhacker","year":"2014","journal-title":"Br J Psychiatry."},{"key":"B67","doi-asserted-by":"publisher","first-page":"615","DOI":"10.2165\/00023210-200923070-00006","article-title":"The efficacy and safety of blonanserin compared with haloperidol in acute-phase schizophrenia: a randomized, double-blind, placebo-controlled, multicentre study","volume":"23","author":"Garcia","year":"2009","journal-title":"CNS Drugs."},{"key":"B68","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1055\/s-2004-832684","article-title":"Olanzapine versus flupenthixol in the treatment of inpatients with schizophrenia: a randomized double-blind trial","volume":"37","author":"Gattaz","year":"2004","journal-title":"Pharmacopsychiatry."},{"key":"B69","doi-asserted-by":"publisher","first-page":"231","DOI":"10.2165\/00044011-200828040-00004","article-title":"Bioequivalence of clozapine orally disintegrating 100-mg tablets compared with clozapine solid oral 100-mg tablets after multiple doses in patients with schizophrenia","volume":"28","author":"Golden","year":"2008","journal-title":"Clin Drug Investig."},{"key":"B70","doi-asserted-by":"publisher","first-page":"516","DOI":"10.4088\/JCP.v63n0609","article-title":"A 28-week comparison of ziprasidone and haloperidol in outpatients with stable schizophrenia","volume":"63","author":"Hirsch","year":"2002","journal-title":"J Clin Psychiatry."},{"key":"B71","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1016\/j.pnpbp.2009.05.014","article-title":"Safety and tolerability of deltoid and gluteal injections of paliperidone palmitate in schizophrenia","volume":"33","author":"Hough","year":"2009","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry."},{"key":"B72","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.pnpbp.2017.10.021","article-title":"A randomized, 13-week study assessing the efficacy and metabolic effects of paliperidone palmitate injection and olanzapine in first-episode schizophrenia patients","volume":"81","author":"Huang","year":"2018","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry."},{"key":"B73","first-page":"811","article-title":"Efficacy and safety of zotepine for the treatment of Taiwanese schizophrenic patients: a double-blind comparison with haloperidol","volume":"100","author":"Hwang","year":"2001","journal-title":"J Formos Med Assoc."},{"key":"B74","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/j.schres.2014.12.013","article-title":"Efficacy and safety of aripiprazole once-monthly in Asian patients with schizophrenia: a multicenter, randomized, double-blind, non-inferiority study versus oral aripiprazole","volume":"161","author":"Ishigooka","year":"2015","journal-title":"Schizophr Res."},{"key":"B75","doi-asserted-by":"publisher","first-page":"832","DOI":"10.4088\/JCP.v68n0603","article-title":"Efficacy and tolerability of once-daily extended release quetiapine fumarate in acute schizophrenia: a randomized, double-blind, placebo-controlled study","volume":"68","author":"Kahn","year":"2007","journal-title":"J Clin Psychiatry."},{"key":"B76","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1176\/appi.ajp.160.6.1125","article-title":"Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic","volume":"160","author":"Kane","year":"2003","journal-title":"Am J Psychiatry."},{"key":"B77","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.schres.2006.09.012","article-title":"Treatment of schizophrenia with paliperidone extended-release tablets: a 6-week placebo-controlled trial","volume":"90","author":"Kane","year":"2007","journal-title":"Schizophr Res."},{"key":"B78","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1176\/appi.ajp.2009.07081221","article-title":"Olanzapine long-acting injection: a 24-week, randomized, double-blind trial of maintenance treatment in patients with schizophrenia","volume":"167","author":"Kane","year":"2010","journal-title":"Am J Psychiatry."},{"key":"B79","doi-asserted-by":"publisher","first-page":"349","DOI":"10.4088\/JCP.10m06306","article-title":"randomized placebo-controlled trial of asenapine for the prevention of relapse of schizophrenia after long-term treatment","volume":"72","author":"Kane","year":"2011","journal-title":"J Clin Psychiatry."},{"key":"B80","doi-asserted-by":"publisher","first-page":"617","DOI":"10.4088\/JCP.11m07530","article-title":"Aripiprazole intramuscular depot as maintenance treatment in patients with schizophrenia: a 52-week, multicenter, randomized, double-blind, placebo-controlled study","volume":"73","author":"Kane","year":"2012","journal-title":"J Clin Psychiatry."},{"key":"B81","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.schres.2015.01.038","article-title":"A multicenter, randomized, double-blind, controlled phase 3 trial of fixed-dose brexpiprazole for the treatment of adults with acute schizophrenia","volume":"164","author":"Kane","year":"2015","journal-title":"Schizophr Res."},{"key":"B82","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1017\/S1461145703003651","article-title":"Efficacy and safety of aripiprazole vs. haloperidol for long-term maintenance treatment following acute relapse of schizophrenia","volume":"6","author":"Kasper","year":"2003","journal-title":"Int J Neuropsychopharmacol."},{"key":"B83","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1097\/JCP.0b013e31802dda4a","article-title":"Paliperidone extended-release tablets for prevention of symptom recurrence in patients with schizophrenia: a randomized, double-blind, placebo-controlled study","volume":"27","author":"Kramer","year":"2007","journal-title":"J Clin Psychopharmacol."},{"key":"B84","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/j.eurpsy.2007.03.002","article-title":"A multicentre, randomized, naturalistic, open-label study between aripiprazole and standard of care in the management of community-treated schizophrenic patients Schizophrenia Trial of Aripiprazole: (STAR) study","volume":"22","author":"Kerwin","year":"2007","journal-title":"Eur Psychiatry."},{"key":"B85","first-page":"271","article-title":"Levomepromazine versus chlorpromazine in treatment-resistant schizophrenia: a double-blind randomized trial","volume":"31","author":"Lal","year":"2006","journal-title":"J Psychiatry Neurosci."},{"key":"B86","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1017\/S1092852916000377","article-title":"Asenapine for the treatment of adults with an acute exacerbation of schizophrenia: results from a randomized, double-blind, fixed-dose, placebo-controlled trial with olanzapine as an active control","volume":"22","author":"Landbloom","year":"2017","journal-title":"CNS Spectr."},{"key":"B87","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1111\/j.1600-0447.2006.00887.x","article-title":"The treatment of negative symptoms and deficit states of chronic schizophrenia: olanzapine compared to amisulpride and placebo in a 6-month double-blind controlled clinical trial","volume":"114","author":"Lecrubier","year":"2006","journal-title":"Acta Psychiatr Scand."},{"key":"B88","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1016\/j.pnpbp.2011.02.001","article-title":"A comparative study of paliperidone palmitate and risperidone long-acting injectable therapy in schizophrenia","volume":"35","author":"Li","year":"2011","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry."},{"key":"B89","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1185\/03007995.2012.728524","article-title":"Comparison of quetiapine and risperidone in Chinese Han patients with schizophrenia: results of a single-blind, randomized study","volume":"28","author":"Li","year":"2012","journal-title":"Curr Med Res Opin."},{"key":"B90","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.jpsychires.2015.07.015","article-title":"Comparative study of the efficacy and safety between blonanserin and risperidone for the treatment of schizophrenia in Chinese patients: a double-blind, parallel-group multicenter randomized trial","volume":"69","author":"Li","year":"2015","journal-title":"J Psychiatr Res."},{"key":"B91","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1097\/YIC.0b013e3283633a83","article-title":"Antipsychotic combination using low-dose antipsychotics is as efficacious and safe as, but cheaper, than optimal-dose monotherapy in the treatment of schizophrenia: a randomized, double-blind study","volume":"28","author":"Lin","year":"2013","journal-title":"Int Clin Psychopharmacol."},{"key":"B92","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1056\/NEJMoa051688","article-title":"Effectiveness of antipsychotic drugs in patients with chronic schizophrenia","volume":"353","author":"Lieberman","year":"2005","journal-title":"N Engl J Med."},{"key":"B93","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.schres.2013.01.009","article-title":"Efficacy and safety of lurasidone 80 mg\/day and 160 mg\/day in the treatment of schizophrenia: a randomized, double-blind, placebo- and active-controlled trial","volume":"145","author":"Loebel","year":"2013","journal-title":"Schizophr Res."},{"key":"B94","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1017\/S1092852913000904","article-title":"Daytime sleepiness associated with lurasidone and quetiapine XR: results from a randomized double-blind, placebo-controlled trial in patients with schizophrenia","volume":"19","author":"Loebel","year":"2014","journal-title":"CNS Spectr."},{"key":"B95","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1097\/YIC.0b013e3281c55f4f","article-title":"A double-blind, placebo-controlled, randomized study evaluating the effect of paliperidone extended-release tablets on sleep architecture in patients with schizophrenia","volume":"22","author":"Luthringer","year":"2007","journal-title":"Int Clin Psychopharmacol."},{"key":"B96","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1016\/j.biopsych.2007.01.017","article-title":"Efficacy and safety of paliperidone extended-release tablets: results of a 6-week, randomized, placebo-controlled study","volume":"62","author":"Marder","year":"2007","journal-title":"Biol Psychiatry."},{"key":"B97","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1176\/appi.ajp.2011.10060907","article-title":"Lurasidone in the treatment of schizophrenia: a randomized, double-blind, placebo- and olanzapine-controlled study","volume":"168","author":"Meltzer","year":"2011","journal-title":"Am J Psychiatry."},{"key":"B98","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.4088\/JCP.14m09741","article-title":"A randomized, double-blind, placebo-controlled trial of aripiprazole lauroxil in acute exacerbation of schizophrenia","volume":"76","author":"Meltzer","year":"2015","journal-title":"J Clin Psychiatry."},{"key":"B99","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1016\/j.schres.2015.07.007","article-title":"Qualify: a randomized head-to-head study of aripiprazole once-monthly and paliperidone palmitate in the treatment of schizophrenia","volume":"168","author":"Naber","year":"2015","journal-title":"Schizophr Res."},{"key":"B100","doi-asserted-by":"publisher","first-page":"829","DOI":"10.4088\/JCP.08m04905","article-title":"Lurasidone in the treatment of acute schizophrenia: a double-blind, placebo-controlled trial","volume":"70","author":"Nakamura","year":"2009","journal-title":"J Clin Psychiatry."},{"key":"B101","doi-asserted-by":"publisher","first-page":"327","DOI":"10.2147\/DDDT.S95100","article-title":"Clinical pharmacology study of cariprazine (MP-214) in patients with schizophrenia (12-week treatment)","volume":"10","author":"Nakamura","year":"2016","journal-title":"Drug Des Devel Ther."},{"key":"B102","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1097\/JCP.0000000000000479","article-title":"Efficacy, safety, and tolerability of RBP-7000 once-monthly risperidone for the treatment of acute schizophrenia: an 8-week, randomized, double-blind, placebo-controlled, multicenter phase 3 study","volume":"36","author":"Nasser","year":"2016","journal-title":"J Clin Psychopharmacol."},{"key":"B103","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1016\/S0140-6736(17)30060-0","article-title":"Cariprazine versus risperidone monotherapy for treatment of predominant negative symptoms in patients with schizophrenia: a randomised, double-blind, controlled trial","volume":"389","author":"N\u00e9meth","year":"2017","journal-title":"Lancet."},{"key":"B104","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1007\/s00213-012-2838-2","article-title":"Lurasidone in the treatment of schizophrenia: a 6-week, placebo-controlled study","volume":"225","author":"Ogasa","year":"2013","journal-title":"Psychopharmacology."},{"key":"B105","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1097\/01.yic.0000182121.59296.70","article-title":"Ziprasidone and Amisulpride effectively treat negative symptoms of schizophrenia: results of a 12-week, double-blind study","volume":"21","author":"Oli\u00e9","year":"2006","journal-title":"Int Clin Psychopharmacol."},{"key":"B106","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/j.pnpbp.2010.11.008","article-title":"A double-blind study of paliperidone palmitate and risperidone long-acting injectable in adults with schizophrenia","volume":"35","author":"Pandina","year":"2011","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry."},{"key":"B107","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.4088\/JCP.v64n0910","article-title":"Aripiprazole for the prevention of relapse in stabilized patients with chronic schizophrenia: a placebo-controlled 26-week study","volume":"64","author":"Pigott","year":"2003","journal-title":"J Clin Psychiatry."},{"key":"B108","doi-asserted-by":"publisher","first-page":"1492","DOI":"10.4088\/JCP.v68n1004","article-title":"Efficacy and tolerability of asenapine in acute schizophrenia: a placebo- and risperidone-controlled trial","volume":"68","author":"Potkin","year":"2007","journal-title":"J Clin Psychiatry."},{"key":"B109","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1177\/2045125315606027","article-title":"A 6-week, double-blind, placebo- and haloperidol-controlled, phase II study of lurasidone in patients with acute schizophrenia","volume":"5","author":"Potkin","year":"2015","journal-title":"Ther Adv Psychopharmacol."},{"key":"B110","first-page":"137","article-title":"Neuropsychological change in patients with schizophrenia after treatment with quetiapine or haloperidol","volume":"26","author":"Purdon","year":"2001","journal-title":"J Psychiatry Neurosci."},{"key":"B111","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1007\/s00406-007-0739-x","article-title":"Effects of risperidone and quetiapine on cognition in patients with schizophrenia and predominantly negative symptoms","volume":"257","author":"Riedel","year":"2007","journal-title":"Eur Arch Psychiatry Clin Neurosci."},{"key":"B112","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.schres.2014.12.027","article-title":"Comparison of the effects of quetiapine extended-release and quetiapine immediate-release on cognitive performance, sedation and patient satisfaction in patients with schizophrenia: a randomised, double-blind, crossover study (eXtRa)","volume":"162","author":"Riedel","year":"2015","journal-title":"Schizophr Res."},{"key":"B113","doi-asserted-by":"publisher","first-page":"pyw018","DOI":"10.1093\/ijnp\/pyw018","article-title":"Efficacy and safety of paliperidone palmitate 3-month formulation for patients with schizophrenia: a randomized, multicenter, double-blind, noninferiority study","volume":"19","author":"Savitz","year":"2016","journal-title":"Int J Neuropsychopharmacol"},{"key":"B114","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.schres.2009.05.002","article-title":"Ziprasidone vs clozapine in schizophrenia patients refractory to multiple antipsychotic treatments: the MOZART study","volume":"113","author":"Sacchetti","year":"2009","journal-title":"Schizophr Res."},{"key":"B115","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.jpsychires.2014.02.012","article-title":"A 6-week randomized, double-blind, placebo-controlled, comparator referenced trial of vabicaserin in acute schizophrenia","volume":"53","author":"Shen","year":"2014","journal-title":"J Psychiatr Res."},{"key":"B116","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1002\/hup.763","article-title":"Quetiapine versus olanzapine for the treatment of negative symptoms in patients with schizophrenia","volume":"21","author":"Sirota","year":"2006","journal-title":"Hum Psychopharmacol."},{"key":"B117","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1001\/archpsyc.1997.01830180067009","article-title":"Quetiapine in patients with schizophrenia. A high- and low-dose double-blind comparison with placebo Seroquel Study Group","volume":"54","author":"Small","year":"1997","journal-title":"Arch Gen Psychiatry."},{"key":"B118","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1097\/01.jcp.0000168486.14516.7c","article-title":"Rapid dose escalation with quetiapine: a pilot study","volume":"25","author":"Smith","year":"2005","journal-title":"J Clin Psychopharmacol."},{"key":"B119","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1176\/ajp.2006.163.4.611","article-title":"Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic","volume":"163","author":"Stroup","year":"2006","journal-title":"Am J Psychiatry."},{"key":"B120","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1176\/ajp.2007.164.3.415","volume":"164","author":"Stroup","year":"2007","journal-title":"Effectiveness of olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia after discontinuing perphenazine: a CATIE study. Am J Psychiatry."},{"key":"B121","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.pnpbp.2012.09.010","article-title":"A 12-week randomized, open-label study of perospirone versus aripiprazole in the treatment of Japanese schizophrenia patients","volume":"40","author":"Takekita","year":"2013","journal-title":"Progr Neuropsychopharmacol Biol Psychiatry."},{"key":"B122","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.euroneuro.2014.12.008","article-title":"Effectiveness of different dosing regimens of risperidone and olanzapine in schizophrenia","volume":"25","author":"Takeuchi","year":"2015","journal-title":"Eur Neuropsychopharmacol."},{"key":"B123","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1177\/0269881115620460","article-title":"A double-blind, placebo-controlled, randomized withdrawal study of lurasidone for the maintenance of efficacy in patients with schizophrenia","volume":"30","author":"Tandon","year":"2016","journal-title":"J Psychopharmacol."},{"key":"B124","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1097\/JGP.0b013e31815a3e7a","article-title":"Safety and tolerability of oral paliperidone extended-release tablets in elderly patients with schizophrenia: a double-blind, placebo-controlled study with six-month open-label extension","volume":"16","author":"Tzimos","year":"2008","journal-title":"Am J Geriatr Psychiatry."},{"key":"B125","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1007\/s40263-016-0345-4","article-title":"A randomized trial of iloperidone for prevention of relapse in schizophrenia: the REPRIEVE study","volume":"30","author":"Weiden","year":"2016","journal-title":"CNS Drugs."},{"key":"B126","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.4088\/JCP.v67n0712","article-title":"Comparison of quetiapine and risperidone in the treatment of schizophrenia: a randomized, double-blind, flexible-dose, 8-week study","volume":"67","author":"Zhong","year":"2006","journal-title":"J f Clin Psychiatry."},{"key":"B127","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.schres.2019.11.014","article-title":"Sleep and schizophrenia: from epiphenomenon to treatable causal target","volume":"221","author":"Waite","year":"2020","journal-title":"Schizoph Res."},{"key":"B128","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.sleep.2016.04.003","article-title":"Atypical antipsychotics for insomnia: a systematic review","volume":"22","author":"Thompson","year":"2016","journal-title":"Sleep Med."},{"key":"B129","doi-asserted-by":"publisher","first-page":"621691","DOI":"10.3389\/fphar.2021.621691","article-title":"Head-to-head comparison of sedation and somnolence among 37 antipsychotics in schizophrenia, bipolar disorder, major depression, autism spectrum disorders, delirium, and repurposed in COVID-19, infectious diseases, and oncology from the FAERS 2004-2020","volume":"12","author":"Eugene","year":"2021","journal-title":"Front Pharmacol"},{"key":"B130","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.2147\/NDT.S134340","article-title":"Comparative efficacy and safety of antipsychotics in the treatment of schizophrenia: a network meta-analysis in a Japanese population","volume":"13","author":"Kishi","year":"2017","journal-title":"Neuropsychiatr Dis Treat."},{"key":"B131","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.schres.2013.11.009","article-title":"Olanzapine and clozapine differently affect sleep in patients with schizophrenia: results from a double-blind, polysomnographic study and review of the literature","volume":"152","author":"Kluge","year":"2014","journal-title":"Schizophr Res."},{"key":"B132","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1097\/01.jcp.0000095347.32154.08","article-title":"Improvement in indices of health status in outpatients with schizophrenia switched to ziprasidone","volume":"23","author":"Weiden","year":"2003","journal-title":"J Clin Psychopharmacol."},{"key":"B133","doi-asserted-by":"publisher","first-page":"5094017","DOI":"10.1155\/2019\/5094017","article-title":"Attitude towards antipsychotic medications in patients diagnosed with schizophrenia: a cross-sectional study at Amanuel Mental Specialized Hospital, Addis Ababa, Ethiopia","volume":"2019","author":"Kassew","year":"2019","journal-title":"Schizophr Res Treat."},{"key":"B134","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1007\/s40263-016-0352-5","article-title":"Antipsychotic drug-induced somnolence: incidence, mechanisms, and management","volume":"30","author":"Fang","year":"2016","journal-title":"CNS Drugs."},{"key":"B135","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1080\/14740338.2016.1201475","article-title":"An update of safety of clinically used atypical antipsychotics","volume":"15","author":"Orsolini","year":"2016","journal-title":"Expert Opin Drug Saf."},{"key":"B136","doi-asserted-by":"publisher","first-page":"173","DOI":"10.2174\/1574886314666190301152734","article-title":"Positive and negative effects of antipsychotic medication: an international online survey of 832 recipients","volume":"14","author":"Read","year":"2019","journal-title":"Curr Drug Saf."},{"key":"B137","first-page":"3","article-title":"Atypical antipsychotics: sleep, sedation, and efficacy","volume":"6","author":"Miller","year":"2004","journal-title":"J Clin Psychiatry"},{"key":"B138","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.12669\/pjms.315.8998","article-title":"Antipsychotic medication and QT prolongation","volume":"31","author":"Chohan","year":"2015","journal-title":"Pak J Med Sci Q."},{"key":"B139","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1176\/appi.ajp.157.7.1041","article-title":"Toward reformulating the diagnosis of schizophrenia","volume":"157","author":"Tsuang","year":"2000","journal-title":"Am J Psychiatry."}],"container-title":["Frontiers in Psychiatry"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2023.1189768\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,27]],"date-time":"2023-06-27T11:53:22Z","timestamp":1687866802000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2023.1189768\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,27]]},"references-count":139,"alternative-id":["10.3389\/fpsyt.2023.1189768"],"URL":"https:\/\/doi.org\/10.3389\/fpsyt.2023.1189768","relation":{},"ISSN":["1664-0640"],"issn-type":[{"value":"1664-0640","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,27]]},"article-number":"1189768"}}